文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

新型抗癌RXR激动剂IRX4204减轻小鼠急性GVHD并保留移植物抗白血病效应

Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses.
PubMed 文献 · Blood · 2021-01-01

本研究在小鼠模型中比较了新型RXR激动剂IRX4204与FK506对急性GVHD的作用。IRX4204通过抑制供者T细胞增殖、减少Th1分化、促进Treg生成并增强Treg稳定性,减轻肠道损伤和炎症因子水平,同时保留对白血病和淋巴瘤细胞的移植物抗白血病反应,并在人MLR中降低T细胞增殖、促进Treg生成。

要点

  • IRX4204在减轻小鼠急性GVHD方面优于FK506
  • IRX4204促进Treg生成并维持其稳定性
  • IRX4204保留抗白血病和淋巴瘤的GVL效应

核心结论

  • 靶向RXR的IRX4204可能成为预防临床急性GVHD的新方法。

研究设计与样本

  • 小鼠急性GVHD模型,比较IRX4204与FK506的体内效果。
  • 体外实验包括naive CD4+ T细胞诱导Treg分化及人混合淋巴细胞反应。
  • 使用Foxp3谱系追踪小鼠追踪Treg起源和当前Foxp3表达。

主要发现

  • IRX4204在减轻急性GVHD方面优于FK506,与抑制供者T细胞增殖、减少Th1分化、促进Treg生成相关。
  • 受者IRX4204治疗减少肠道损伤并降低血清IFN-γ和TNF-α水平。
  • IRX4204处理的GVHD小鼠供者T细胞中促炎通路转录本显著减少。
  • IRX4204增强体外naive CD4+ T细胞向Treg分化,并增加GVHD小鼠中供者Foxp3- T细胞向Foxp3+ Treg的转化。
  • IRX4204支持Treg稳定性,且处理后的受者保留针对白血病和淋巴瘤细胞的GVL反应。

临床怎么用

  • IRX4204可能作为急性GVHD预防策略,同时保留GVL效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The nuclear receptor (NR) subclass, retinoid X receptors (RXRs), exert immunomodulatory functions that control inflammation and metabolism via homodimers and heterodimers, with several other NRs, including retinoic acid receptors. IRX4204 is a novel, highly specific RXR agonist in clinical trials that potently and selectively activates RXR homodimers, but not heterodimers. In this study, in vivo IRX4204 compared favorably with FK506 in abrogating acute graft-versus-host disease (GVHD), which was associated with inhibiting allogeneic donor T-cell proliferation, reducing T-helper 1 differentiation, and promoting regulatory T-cell (Treg) generation. Recipient IRX4204 treatment reduced intestinal injury and decreased IFN-γ and TNF-α serum levels. Transcriptional analysis of donor T cells isolated from intestines of GVHD mice treated with IRX4204 revealed significant decreases in transcripts regulating proinflammatory pathways. In vitro, inducible Treg differentiation from naive CD4+ T cells was enhanced by IRX4204. In vivo, IRX4204 increased the conversion of donor Foxp3- T cells into peripheral Foxp3+ Tregs in GVHD mice. Using Foxp3 lineage-tracer mice in which both the origin and current FoxP3 expression of Tregs can be tracked, we demonstrated that IRX4204 supports Treg stability. Despite favoring Tregs and reducing Th1 differentiation, IRX4204-treated recipients maintained graft-versus-leukemia responses against both leukemia and lymphoma cells. Notably, IRX4204 reduced in vitro human T-cell proliferation and enhanced Treg generation in mixed lymphocyte reaction cultures. Collectively, these beneficial effects indicate that targeting RXRs with IRX4204 could be a novel approach to preventing acute GVHD in the clinic.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Thangavelu G, Wang C, Loschi M, et al. Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. Blood. 2021. PMID: 32976550. doi:10.1182/blood.2020005628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。